Development of advanced nanoparticle based scaffolds for the management of diabetic wounds
Human beta defensin-2 loaded PLGA nanoparticles impregnated in collagen-chitosan composite scaffold for diabetic wounds management
Diabetic wounds (DW) represent a severe challenge in modern healthcare due to their complex nature and the associated risks of infections, prolonged healing, and even amputations. Recognizing these challenges, Arni Medica has collaborated with Research institutes to develop innovative solutions for diabetic wound management.
As part of this collaboration, a groundbreaking study was conducted to formulate and evaluate Human Beta Defensin-2 (HBD-2)-loaded PLGA nanoparticles incorporated into a collagen-chitosan (COL-CS) composite scaffold. This research showcased a multi-functional treatment approach to address the intricate pathophysiology of diabetic wounds, including inflammation, impaired cell migration, and angiogenesis.
As part of this collaboration, a groundbreaking study was conducted to formulate and evaluate Human Beta Defensin-2 (HBD-2)-loaded PLGA nanoparticles incorporated into a collagen-chitosan (COL-CS) composite scaffold. This research showcased a multi-functional treatment approach to address the intricate pathophysiology of diabetic wounds, including inflammation, impaired cell migration, and angiogenesis.
Key Highlights of the Research:
- Enhanced Healing Properties: The HBD-2-loaded COL-CS scaffold demonstrated significant antibacterial, anti-inflammatory, and pro-angiogenic properties. In vitro and in vivo studies revealed accelerated healing and reduced inflammatory markers compared to conventional methods.
- Innovative Scaffold Design: Biodegradable and biocompatible scaffolds with optimized porosity and mechanical strength facilitated sustained drug release and improved cell proliferation.
- Anti-Microbial and Anti-Inflammatory Effects: The HBD-2 COL-CS scaffolds effectively reduced levels of harmful bacteria, such as S. aureus, E. coli, and P. aeruginosa, while promoting the production of beneficial growth factors for wound recovery.
This collaboration highlights Arni Medica's commitment to leveraging cutting-edge biotechnology to address critical healthcare challenges. The findings of this research, published in Biomedicine & Pharmacotherapy (DOI: 10.1016/j.biopha.2023.114540), are a testament to the power of academic-industry partnerships in driving innovation.
Stay tuned as we continue to push the boundaries of medical research and innovation to improve patient outcomes.
